Risk of venous thromboembolism with CDK 4/6 inhibitor use in breast cancer: A systematic review and meta-analysis.
Open Access
- 11 July 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (8)
Abstract
Hormone receptor-positive (HR+), HER2 negative, non-metastatic breast cancer represents a significant proportion of early-stage breast cancer. The introduction of cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors combined with endocrine therapy (ET), have significantly improved disease free survival. Existing studies suggest that CDK 4/6 inhibitors are associated with an increased risk of venous thromboembolism (VTE). We further studied this risk. The databases Medline, Embase, and Cochrane Central Register of Controlled Trials (Central) were searched. 4,624 publications were screened for inclusion, and seven studies were selected for data extraction and analysis. Publications included studied patients who had a diagnosis of non-metastatic breast cancer and received treatment with CKD 4/6 inhibitors. Major exclusion criteria included age <18 years-old, metastatic cancer, and patients already diagnosed with a hypercoagulable disorder. The statistical analysis was performed using RevMan 9.19.0. We reported information in Risk Ratio (RR) and pooled the information with a random-effect meta-analysis according to the heterogeneity expected. We observed the incidence of VTE in the group of patients treated with CDK 4/6 inhibitors to be larger (68/3165) than the incidence of VTE in patients treated with ET alone (11/2205). We found the relative risk of developing VTE was significantly higher with CDK 4/6 inhibitor treatment than with treatment with ET alone (RR 3.8, 95% CI 2.0 to 7.2). Overall, there was not a significant variability in effect estimates from the included studies (I2=0%). As the use of CDK 4/6 grows, this information will help conversations about risks and benefits when selecting treatment plans.Keywords
This publication has 12 references indexed in Scilit:
- Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic reviewExpert Opinion on Drug Safety, 2023
- Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancerTherapeutic Advances in Medical Oncology, 2023
- Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL TrialThe Oncologist, 2022
- Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysisThrombosis Research, 2021
- CDK 4/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real‐world practiceEuropean Journal of Haematology, 2021
- MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III studyTherapeutic Advances in Medical Oncology, 2020
- Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialThe Lancet Oncology, 2020
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2JAMA Oncology, 2020
- Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerJNCI: Journal of the National Cancer Institute, 2018
- Tamoxifen and risk of idiopathic venous thromboembolismBritish Journal of Clinical Pharmacology, 1998